Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1967 1
1971 3
1972 1
1973 3
1974 3
1976 1
1981 2
1983 1
1985 3
1986 2
1987 3
1988 4
1989 4
1990 2
1991 3
1992 6
1993 1
1994 5
1995 13
1996 15
1997 29
1998 25
1999 31
2000 35
2001 42
2002 69
2003 70
2004 66
2005 83
2006 100
2007 132
2008 135
2009 168
2010 165
2011 191
2012 218
2013 226
2014 206
2015 236
2016 241
2017 255
2018 260
2019 250
2020 270
2021 302
2022 188
Text availability
Article attribute
Article type
Publication date

Search Results

3,600 results
Results by year
Filters applied: . Clear all
Page 1
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.
Makker V, Colombo N, Casado Herráez A, Santin AD, Colomba E, Miller DS, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Ushijima K, Sakata J, Yonemori K, Kim YM, Guerra EM, Sanli UA, McCormack MM, Smith AD, Keefe S, Bird S, Dutta L, Orlowski RJ, Lorusso D; Study 309–KEYNOTE-775 Investigators. Makker V, et al. Among authors: kim ym. N Engl J Med. 2022 Feb 3;386(5):437-448. doi: 10.1056/NEJMoa2108330. Epub 2022 Jan 19. N Engl J Med. 2022. PMID: 35045221 Clinical Trial.
Survival with Cemiplimab in Recurrent Cervical Cancer.
Tewari KS, Monk BJ, Vergote I, Miller A, de Melo AC, Kim HS, Kim YM, Lisyanskaya A, Samouëlian V, Lorusso D, Damian F, Chang CL, Gotovkin EA, Takahashi S, Ramone D, Pikiel J, Maćkowiak-Matejczyk B, Guerra Alía EM, Colombo N, Makarova Y, Rischin D, Lheureux S, Hasegawa K, Fujiwara K, Li J, Jamil S, Jankovic V, Chen CI, Seebach F, Weinreich DM, Yancopoulos GD, Lowy I, Mathias M, Fury MG, Oaknin A; Investigators for GOG Protocol 3016 and ENGOT Protocol En-Cx9. Tewari KS, et al. Among authors: kim ym. N Engl J Med. 2022 Feb 10;386(6):544-555. doi: 10.1056/NEJMoa2112187. N Engl J Med. 2022. PMID: 35139273 Clinical Trial.
B7-H3×4-1BB bispecific antibody augments antitumor immunity by enhancing terminally differentiated CD8+ tumor-infiltrating lymphocytes.
You G, Lee Y, Kang YW, Park HW, Park K, Kim H, Kim YM, Kim S, Kim JH, Moon D, Chung H, Son W, Jung UJ, Park E, Lee S, Son YG, Eom J, Won J, Park Y, Jung J, Lee SW. You G, et al. Among authors: kim ym. Sci Adv. 2021 Jan 15;7(3):eaax3160. doi: 10.1126/sciadv.aax3160. Print 2021 Jan. Sci Adv. 2021. PMID: 33523913 Free PMC article.
Exogenous mitochondrial transfer and endogenous mitochondrial fission facilitate AML resistance to OxPhos inhibition.
Saito K, Zhang Q, Yang H, Yamatani K, Ai T, Ruvolo V, Baran N, Cai T, Ma H, Jacamo R, Kuruvilla V, Imoto J, Kinjo S, Ikeo K, Moriya K, Suzuki K, Miida T, Kim YM, Vellano CP, Andreeff M, Marszalek JR, Tabe Y, Konopleva M. Saito K, et al. Among authors: kim ym. Blood Adv. 2021 Oct 26;5(20):4233-4255. doi: 10.1182/bloodadvances.2020003661. Blood Adv. 2021. PMID: 34507353 Free PMC article.
Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial.
Youn JW, Hur SY, Woo JW, Kim YM, Lim MC, Park SY, Seo SS, No JH, Kim BG, Lee JK, Shin SJ, Kim K, Chaney MF, Choi YJ, Suh YS, Park JS, Sung YC. Youn JW, et al. Among authors: kim ym. Lancet Oncol. 2020 Dec;21(12):1653-1660. doi: 10.1016/S1470-2045(20)30486-1. Lancet Oncol. 2020. PMID: 33271094 Clinical Trial.
Cysteine oxidation of copper transporter CTR1 drives VEGFR2 signalling and angiogenesis.
Das A, Ash D, Fouda AY, Sudhahar V, Kim YM, Hou Y, Hudson FZ, Stansfield BK, Caldwell RB, McMenamin M, Littlejohn R, Su H, Regan MR, Merrill BJ, Poole LB, Kaplan JH, Fukai T, Ushio-Fukai M. Das A, et al. Among authors: kim ym. Nat Cell Biol. 2022 Jan;24(1):35-50. doi: 10.1038/s41556-021-00822-7. Epub 2022 Jan 13. Nat Cell Biol. 2022. PMID: 35027734 Free PMC article.
3,600 results